Reaction
Mycoplasma Infection reporting signals
As of the last recalculation, Mycoplasma Infection appears in 765 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 100.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 41 | 100.2 | 100.5 |
| Micafungin Sodium | 14 | 45.7 | 45.8 |
| Tacrolimus Ointment 0.1% | 131 | 34.3 | 34.4 |
| Tacrolimus Extended-Release Capsules | 131 | 34.2 | 34.3 |
| Cefazolin | 10 | 30.2 | 30.2 |
| Mycophenolate Mofetil | 122 | 28.9 | 28.9 |
| Mycophenolate Mofetil Hydrochloride | 122 | 28.8 | 28.9 |
| Tacrolimus | 135 | 28.3 | 28.3 |
| Cefazolin Sodium | 12 | 27.5 | 27.5 |
| Thiotepa | 9 | 25.9 | 26.0 |
| Busulfan | 14 | 24.6 | 24.7 |
| Entecavir | 10 | 23.6 | 23.6 |
| Valganciclovir Hydrochloride Powder, | 10 | 22.6 | 22.6 |
| Azithromycin | 31 | 21.8 | 21.8 |
| Azithromycin Monohydrate | 31 | 21.1 | 21.1 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 20.4 | 20.4 |
| Sirolimus | 9 | 18.4 | 18.4 |
| Palivizumab | 10 | 17.9 | 17.9 |
| Linagliptin | 11 | 16.6 | 16.6 |
| Voriconazole Injection | 13 | 16.6 | 16.6 |
| Benralizumab | 7 | 9.6 | 9.6 |
| Copper | 4 | 2.5 | 2.5 |